Needham & Company LLC Reaffirms “Hold” Rating for Omeros (NASDAQ:OMER)

Needham & Company LLC restated their hold rating on shares of Omeros (NASDAQ:OMER) in a research note released on Friday,Benzinga reports.

Several other research analysts also recently commented on the stock. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Thursday. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Finally, Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Price Performance

Omeros stock opened at $9.33 on Friday. The firm’s 50 day moving average price is $9.35 and its 200-day moving average price is $6.00. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60. The stock has a market cap of $540.67 million, a P/E ratio of -4.04 and a beta of 2.01.

Institutional Trading of Omeros

A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its stake in shares of Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares during the period. MML Investors Services LLC raised its position in Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the period. SPC Financial Inc. purchased a new stake in Omeros in the 3rd quarter worth about $77,000. SG Americas Securities LLC bought a new stake in Omeros in the third quarter worth about $80,000. Finally, AQR Capital Management LLC purchased a new position in shares of Omeros during the second quarter valued at approximately $105,000. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.